Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis

• DOI: 10.1186/s12969-017-0147-3
• Publication Date: 2017-03-14T03:24:29Z
• Authors: Boris Hügle; Fabian Speth; Johannes-Peter Haas
• Keywords: Male; 0301 basic medicine; Adolescent; Short Report; Antibodies, Monoclonal, Humanized; canakinumab; systemic JIA; 03 medical and health sciences; 0302 clinical medicine; Rheumatology; inflammatory bowel disease; Immunology and Allergy; Humans; Pediatrics, Perinatology, and Child Health; Antibodies, Monoclonal; Colonoscopy; 610 Medical sciences; Medicine; Inflammatory Bowel Diseases; Arthritis, Juvenile; 3. Good health; Interleukin 1 Receptor Antagonist Protein; Treatment Outcome; ddc: 610; Antirheumatic Agents; anakinra

Background: Inflammatory bowel disease can develop with some rheumatic diseases in childhood, including juvenile idiopathic arthritis (JIA). Systemic onset JIA has not been connected to inflammatory bowel disease (IBD), but might be connected especially in the context of new treatments. Methods: [for full text, please go to the a.m. URL]<br/>44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)<br/>